Biotech News
Related news
RXSTRxSight2026-08-05 20:05 EST
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
RXSTRxSight2026-07-06 20:15 EST
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
SSKNStrata Skin Sciences2026-07-28 13:15 EST
STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer
IARTIntegra LifeSciences2026-06-23 12:00 EST
Integra LifeSciences Announces Key Executive Appointments
STIMNeuronetics2026-07-20 20:05 EST
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
IARTIntegra LifeSciences2026-07-02 12:30 EST
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
CVRXCVRx2026-06-09 11:30 EST
CVRx Announces Chief Financial Officer Transition
DNLIDenali Therapeutics2026-05-21 22:00 EST
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
RxSight
Adjustable Cataract Lenses RxSight is an ophthalmic medical-device company focused on customized vision after cataract surgery. Light Adjustable Lens System The system combines an implantable Light Adjustable Lens with a Light Delivery Device. After surgery, physicians use ultraviolet light treatments to modify the lens and refine the...
Recent company news
RXSTRxSight2026-08-05 20:05 EST
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
RXSTRxSight2026-07-26 20:00 EST
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RXSTRxSight2026-07-15 20:15 EST
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
RXSTRxSight2026-07-06 20:16 EST
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
RXSTRxSight2026-07-06 20:15 EST
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
Stock data
- Close
- 6.08 USD
- Market cap
- 204.5M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
